Objective To explore the clinical effect of pirfenidone in the treatment of idiopathic pulmonary fibrosis.Methods Sixty patients with idiopathic pulmonary fibrosis admitted to a hospital in Dandong from August 2016 to May 2018 were selected as the research subjects.The patients were divided into a control group and an observation group using a random number table

with 30 cases in each group.Patients in the control group were treated with oral prednisone acetate

while patients in the observation group were given pirfenidone in addition.The peak expiratory flow（PEF）

forced expiratory volume in 1 second（FEV

1

）

forced vital capacity（FVC）

partial pressure of oxygen（PaO

2

）

levels of interleukin-6（IL-6）before treatment and at week 16 of treatment were compared between the two groups.The incidence of adverse reactions at week 16 of treatment was compared between the two groups.Results After treatment

the PEF

FEV

1

and FVC of the observation group were（3.58±0.22）L/s

（1.97±0.20）L and（1.99±0.10）L

all significantly greater than those of the control group

which were（3.02±0.17）L/s

（1.77±0.23）L and（1.76±0.26）L

respectively

and the PEF

FEV1 and FVC of the two groups were significantly greater than before treatment（all P

<

0.05）.After treatment

the PaO

2

of the observation group was（65.58±7.17）mmHg（1 mmHg=0.133 kPa）

significantly higher than（59.49±6.84）mmHg of the control group

and the PaO

2

of both groups was higher than before treatment（all P

<

0.05）.After treatment

the levels of IL-6 in the observation group were（13.77±1.62）pg/mL

significantly lower than those in the control group

which were（15.30±1.53）pg/mL

and the levels of IL-6 in the two groups were significantly lower than before treatment（P

<

0.05）.The incidence of adverse reactions in both groups was low

and the difference was not statistically significant（P

>

0.05）.Conclusion The clinical effect of pirfenidone combined with prednisone acetate in treating idiopathic pulmonary fibrosis is significant.It can effectively improve the lung function of patients

reduce the levels of IL-6 and increase the PaO

2

level.It is safe

reliable

and worthy of wider clinical application.